Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2506 to 2520 of 8933 results

  1. Durvalumab with tremelimumab and chemotherapy for treating unresectable or advanced urothelial cancer [ID3855]

    Awaiting development Reference number: GID-TA10748 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Dusquetide for treating oral mucositis during chemoradiation for head and neck cancer [ID3830]

    Awaiting development Reference number: GID-TA10715 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Naxitamab with GM-CSF for treating relapsed or refractory high-risk neuroblastoma [ID3769]

    Awaiting development Reference number: GID-TA10638 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Implanting a baroreceptor stimulation device for resistant hypertension

    In development Reference number: GID-IP1180 Expected publication date: TBC

    Interventional procedures guidance
    In development

  5. Port Delivery Platform with ranibizumab for treating wet age-related macular degeneration [ID3983]

    Awaiting development Reference number: GID-TA10879 Expected publication date:  11 November 2026

    Technology appraisal guidance
    Awaiting development

  6. Timrepigene emparvovec for treating choroideremia [ID3916]

    Awaiting development Reference number: GID-TA10787 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Remibrutinib for treating chronic inducible urticaria inadequately controlled by H1-antihistamines [ID6742]

    Awaiting development Reference number: GID-TA11968 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Gilteritinib with standard chemotherapy for newly diagnosed FLT3-mutation-positive acute myeloid leukaemia when intensive chemotherapy is suitable [ID6704]

    Awaiting development Reference number: GID-TA11948 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after 2 or more systemic treatments (review of TA987) [ID6619]

    In development Reference number: GID-TA11823 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Helge for detecting haemolysis

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation

  11. Vonicog alfa for preventing haemorrhage in people with von Willebrand disease when desmopressin is ineffective or not suitable [ID6272]

    Topic prioritisation

    Health technology evaluations
    Topic prioritisation

  12. Odronextamab for treating relapsed or refractory follicular lymphoma [ID6726]

    Awaiting development Reference number: GID-TA11829 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Gout

    Awaiting development Reference number: GID-QS10100 Expected publication date: TBC

    Quality standard
    Awaiting development

  14. Topical tapinarof for treating mild to severe plaque psoriasis [ID6712]

    Awaiting development Reference number: GID-TA11951 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Tozorakimab for treating exacerbations of chronic obstructive pulmonary disease after optimised inhaled dual or triple therapy [ID6711]

    Awaiting development Reference number: GID-TA11944 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development